TapewireFind a company

person · Reporting owner

RIEFLIN WILLIAM JL

Disclosed activity across 3 companies

Tapewire entity
38777
SEC CIK
0001182471

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Lyell Immunopharma, Inc.LYEL · Entity 5757DirectorJune 10, 2026June 12, 2026
RAPT Therapeutics, Inc.RAPT · Entity 62554DirectorMay 22, 2024May 23, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Lyell Immunopharma, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09Direct9,250 Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250

F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

RAPT Therapeutics, Inc.

Report date May 22, 2024 · Filed May 23, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2034-05-21Direct36,490 Reported balance After 2024-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-05-23 · Grant · Acquired 36,490 · Balance 36,490

F1: The Option shall vest in 12 equal monthly installments from date of grant of May 22, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The Option shall vest in 12 equal monthly installments from date of grant of May 22, 2024.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-04-05 transaction · row 1
1 source row

Row 1 · 2024-04-05 · Other · Disposed 5,172 · Balance 0

F1: Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for shares in Parent.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2024-04-05 · Other · Disposed 2,769,168 · Balance 0

F1: Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for shares in Parent.

F2: Shares held by Rieflin Family Trust U/A 4/3/00.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09Direct0 Reported balance After 2024-04-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.20 · Expires 2032-03-02Direct0 Reported balance After 2024-04-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-04-05 · Disposition to issuer · Disposed 80,000 · Balance 0

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.93 · Expires 2031-03-16Direct0 Reported balance After 2024-04-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-04-05 · Disposition to issuer · Disposed 80,000 · Balance 0

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.47 · Expires 2030-02-03Direct0 Reported balance After 2024-04-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-04-05 · Disposition to issuer · Disposed 75,000 · Balance 0

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.06 · Expires 2029-02-06Direct0 Reported balance After 2024-04-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2024-04-05 · Disposition to issuer · Disposed 50,000 · Balance 0

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2028-01-30Direct0 Reported balance After 2024-04-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2024-04-05 · Disposition to issuer · Disposed 225,000 · Balance 0

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for shares in Parent.

F2: Shares held by Rieflin Family Trust U/A 4/3/00.

F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 10, 2026 Filed Jun 12, 2026 20:25 UTC Lyell Immunopharma, Inc. LYEL · Entity 5757 GrantOption (right to buy) · Derivative 9,250 $0.00 Strike: $13.22 $0.00
Disclosure

SEC source: 0001182471-26-000002 · form4-06122026_080603.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:48 UTC Lyell Immunopharma, Inc. LYEL · Entity 5757 GrantOption (right to buy) · Derivative 130,000 $0.00 Strike: $0.40 $0.00
Disclosure

SEC source: 0001415889-25-013719 · form4-05192025_100545.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date.

Read SEC document
June 14, 2024 Filed Jun 17, 2024 20:13 UTC Lyell Immunopharma, Inc. LYEL · Entity 5757 GrantOption (right to buy) · Derivative 130,000 $0.00 Strike: $2.36 $0.00
Disclosure

SEC source: 0001415889-24-017162 · form4-06172024_080620.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date.

Read SEC document
May 23, 2024 Filed May 23, 2024 22:18 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 36,490 $0.00 Strike: $4.63 $0.00
Disclosure

SEC source: 0001415889-24-014378 · form4-05232024_100501.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,490

Underlying: Common Stock · 36,490 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The Option shall vest in 12 equal monthly installments from date of grant of May 22, 2024.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 225,000 Not disclosed Strike: $8.14 Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · derivative · entry 8

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 225,000 shares

Expires 2028-01-30

F3 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_date: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 50,000 Not disclosed Strike: $12.06 Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · derivative · entry 7

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2029-02-06

F3 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_date: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 75,000 Not disclosed Strike: $16.47 Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · derivative · entry 6

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 75,000 shares

Expires 2030-02-03

F3 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_date: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 80,000 Not disclosed Strike: $31.93 Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · derivative · entry 5

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 80,000 shares

Expires 2031-03-16

F3 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_date: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 80,000 Not disclosed Strike: $15.20 Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · derivative · entry 4

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 80,000 shares

Expires 2032-03-02

F3 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_date: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 78,407 Not disclosed Strike: $3.69 Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · derivative · entry 3

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,407 shares

Expires 2033-05-09

F3 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · price: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F3 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than $1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,

F4 · derivative.exercise_date: (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 OtherCommon Stock 2,769,168 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · nonDerivative · entry 2

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for shares in Parent.

F2 · ownership.nature: Shares held by Rieflin Family Trust U/A 4/3/00.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:16 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 OtherCommon Stock 5,172 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-042619 · ownership.xml · nonDerivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for shares in Parent.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 22:48 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 11,871 $7.58 Strike: $8.98 $89,982.18
Disclosure

SEC source: 0001415889-24-009605 · form4-04012024_100439.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,871

Underlying: Common Stock · 11,871 shares

Expires 2034-03-27

F2 · price: This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $90,000.

F1 · derivative.exercise_date: The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2024 with the first installment vesting on March 31, 2024, provided that the reporting person is in service as a director on each such vesting date.

Read SEC document
September 08, 2023 Filed Sep 8, 2023 20:27 UTC Lyell Immunopharma, Inc. LYEL · Entity 5757 GrantOption (right to buy) · Derivative 55,000 $0.00 Strike: $3.19 $0.00
Disclosure

SEC source: 0001209191-23-048786 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2033-09-07

F1 · security: On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy.

F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Persons failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date.

Read SEC document
June 16, 2023 Filed Jun 20, 2023 20:51 UTC Lyell Immunopharma, Inc. LYEL · Entity 5757 GrantOption (right to buy) · Derivative 65,000 $0.00 Strike: $3.19 $0.00
Disclosure

SEC source: 0001209191-23-038449 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date.

Read SEC document
May 24, 2023 Filed May 25, 2023 23:00 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 12,940 $0.00 Strike: $20.93 $0.00
Disclosure

SEC source: 0001209191-23-032297 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,940

Underlying: Common Stock · 12,940 shares

Expires 2033-05-23

F1 · derivative.exercise_date: The Option shall vest on the earlier of (i) May 24, 2024, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
May 10, 2023 Filed May 12, 2023 17:52 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 78,407 $0.00 Strike: $3.69 $0.00
Disclosure

SEC source: 0001209191-23-029189 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,407

Underlying: Common Stock · 78,407 shares

Expires 2033-05-09

F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date.

Read SEC document
March 31, 2023 Filed Apr 11, 2023 00:10 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 6,026 $14.52 Strike: $18.35 $87,497.52
Disclosure

SEC source: 0001209191-23-023945 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,026

Underlying: Common Stock · 6,026 shares

Expires 2033-03-30

F2 · price: This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $87,500.

F1 · derivative.exercise_date: The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2023 with the first installment vesting on March 31, 2023, provided that the reporting person is in service as a director on each such vesting date.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:20 UTC Lyell Immunopharma, Inc. LYEL · Entity 5757 GrantOption (right to buy) · Derivative 65,000 $0.00 Strike: $5.31 $0.00
Disclosure

SEC source: 0001209191-22-035879 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date.

Read SEC document
May 25, 2022 Filed May 26, 2022 22:18 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 8,500 $0.00 Strike: $13.64 $0.00
Disclosure

SEC source: 0001209191-22-032319 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The Option shall vest on the earlier of (i) May 25, 2023, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 21:58 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 5,207 $16.80 Strike: $21.99 $87,477.60
Disclosure

SEC source: 0001209191-22-022616 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,207

Underlying: Common Stock · 5,207 shares

Expires 2032-03-30

F2 · price: This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $87,500.

F1 · derivative.exercise_date: The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2022 with the first installment vesting on March 31, 2022, provided that the reporting person is in service as a director on each such vesting date.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 16:11 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 80,000 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001209191-22-016213 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.

Read SEC document
May 28, 2021 Filed Jun 25, 2021 00:17 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 7,500 $0.00 Strike: $19.30 $0.00
Disclosure

SEC source: 0001593968-21-001695 · primary_01.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-05-27

F1 · derivative.exercise_date: The Option shall vest on the earlier of (i) May 28, 2022, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2022, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
March 17, 2021 Filed Mar 18, 2021 20:22 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 80,000 $0.00 Strike: $31.93 $0.00
Disclosure

SEC source: 0001209191-21-021930 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-03-16

F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.

Read SEC document
November 19, 2020 Filed Nov 20, 2020 20:56 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 PurchaseCommon Stock 10,000 $16.22 $162,200.00
Disclosure

SEC source: 0001593968-20-002227 · primary_01.xml · nonDerivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.90 to $16.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
June 18, 2020 Filed Jun 19, 2020 21:44 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 7,500 $0.00 Strike: $28.27 $0.00
Disclosure

SEC source: 0001209191-20-038011 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-06-17

F1 · derivative.exercise_date: The Option shall vest on the earlier of (i) June 18, 2021, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2021, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
February 04, 2020 Filed Feb 6, 2020 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $16.47 $0.00
Disclosure

SEC source: 0001209191-20-007323 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2030-02-03

F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 23:54 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 ConversionSeries B Preferred Stock · Derivative 100,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-055033 · doc4.xml · derivative · entry 5

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees

Disclosed balance after: 0

Underlying: Common Stock · 16,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.exercise_date: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.expiration_date: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting Person is co-Trustee.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 23:54 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 ConversionSeries A Preferred Stock · Derivative 260,344 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-055033 · doc4.xml · derivative · entry 4

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees

Disclosed balance after: 0

Underlying: Common Stock · 43,390 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.exercise_date: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.expiration_date: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting Person is co-Trustee.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 23:54 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 PurchaseCommon Stock 8,000 $12.00 $96,000.00
Disclosure

SEC source: 0001209191-19-055033 · doc4.xml · nonDerivative · entry 3

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Read SEC document
November 04, 2019 Filed Nov 4, 2019 23:54 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 ConversionCommon Stock 16,666 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-055033 · doc4.xml · nonDerivative · entry 2

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees

Disclosed balance after: 76,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting Person is co-Trustee.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 23:54 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 ConversionCommon Stock 43,390 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-055033 · doc4.xml · nonDerivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees

Disclosed balance after: 60,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: The shares are held directly by Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees, for which the Reporting Person is co-Trustee.

Read SEC document
October 30, 2019 Filed Nov 1, 2019 22:38 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 3,333 $0.00 Strike: $12.00 $0.00
Disclosure

SEC source: 0001209191-19-054776 · doc4.xml · derivative · entry 2

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2029-10-29

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments from the vesting commencement date.

Read SEC document
October 30, 2019 Filed Nov 1, 2019 22:38 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 GrantStock Option (right to buy) · Derivative 15,334 $0.00 Strike: $12.00 $0.00
Disclosure

SEC source: 0001209191-19-054776 · doc4.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,334

Underlying: Common Stock · 15,334 shares

Expires 2029-10-29

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments from the vesting commencement date.

Read SEC document
April 08, 2019 Filed Apr 10, 2019 11:21 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 ConversionSeries B Preferred Stock · Derivative 6,668 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-024198 · doc4.xml · derivative · entry 3

RIEFLIN WILLIAM JL · CIK 0001182471 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 6,668 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F1 · derivative.exercise_date: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F1 · derivative.expiration_date: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F3 · ownership.nature: Shares held by the Rieflin Family Trust U/A 4/3/00.

Read SEC document
April 08, 2019 Filed Apr 10, 2019 11:21 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 ConversionSeries A Preferred Stock · Derivative 50,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-024198 · doc4.xml · derivative · entry 2

RIEFLIN WILLIAM JL · CIK 0001182471 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F1 · derivative.exercise_date: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F1 · derivative.expiration_date: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F3 · ownership.nature: Shares held by the Rieflin Family Trust U/A 4/3/00.

Read SEC document
April 08, 2019 Filed Apr 10, 2019 11:21 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 ConversionCommon Stock 56,668 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-024198 · doc4.xml · nonDerivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,769,168

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.

F2 · ownership.nature: Mr. Rieflin early exercised certain shares of common stock, of which (i) 44,531 shares of common stock granted on January 27, 2016 remain unvested and (ii) 103,906 shares of common stock granted on January 20, 2017 remain unvested.

F3 · ownership.nature: Shares held by the Rieflin Family Trust U/A 4/3/00.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.